All Stories

  1. AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1

    Article • Proceedings of the National Academy of Sciences, May 2026, Proceedings of the National Academy of Sciences

    Fuwen Yuan

  2. Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer

    Article • Genes & Diseases, March 2026, Tsinghua University Press

    Fuwen Yuan

  3. Enhanced NOLC1 promotes cell senescence and represses hepatocellular carcinoma cell proliferation by disturbing the organization of nucleolus

    Article • Aging Cell, May 2017, Wiley

    Fuwen Yuan